Johny Marice
Researchers at the University of Auckland have pinpointed a specific neural circuit within the brainstem, the oldest and most fundamental part of the brain, that appears to play a critical role in the development and maintenance of high blood pressure, also known as hypertension. This groundbreaking discovery, emerging from the Manaaki Manawa Centre for Heart Research, shifts our understanding of hypertension by implicating a previously unrecognized brain region in its pathology and offers a promising new avenue for therapeutic intervention.
The identified area, termed the lateral parafacial region (LPFR), is nestled within the brainstem, a vital structure responsible for regulating essential autonomic functions such as breathing, digestion, and heart rate. Professor Julian Paton, the lead researcher and director of the Centre for Heart Research, explained the intricate connection between this brain region and the act of breathing. "The lateral parafacial region is recruited into action causing us to exhale during a laugh, exercise or coughing," Professor Paton stated in an interview. He further elaborated on the physiological distinction between different types of exhalations. "These exhalations are what we call ‘forced’ and driven by our powerful abdominal muscles. In contrast, a normal exhalation does not need these muscles to contract; it happens because the lungs are elastic." This distinction is crucial, as the research suggests that the forceful exhalations mediated by the LPFR are intrinsically linked to elevated blood pressure.
Unraveling the Link: Breathing Patterns and Vascular Constriction
The study, recently published in the esteemed journal Circulation Research, details how the research team discovered a direct correlation between the activation of the LPFR and the constriction of blood vessels, a primary mechanism that elevates blood pressure. Hypertension is a pervasive global health issue, affecting an estimated 1.28 billion adults worldwide, according to the World Health Organization (WHO). It is a significant risk factor for cardiovascular diseases, stroke, and kidney failure. Historically, treatments have focused on lifestyle modifications and pharmacological interventions targeting the kidneys, adrenal glands, and the vascular system itself. However, this new research introduces the brain, specifically the LPFR, as a central player.
"We’ve unearthed a new region of the brain that is causing high blood pressure. Yes, the brain is to blame for hypertension!" Professor Paton declared, emphasizing the paradigm shift this finding represents. The researchers observed that in conditions characterized by high blood pressure, the LPFR exhibits heightened activity. Crucially, when this region was experimentally inactivated, blood pressure readings returned to normal levels. This direct experimental evidence strongly suggests that the LPFR is not merely an associated factor but a causal element in the pathogenesis of hypertension.
The implications of this discovery are far-reaching, particularly concerning the intricate relationship between breathing patterns and cardiovascular health. The findings suggest that certain breathing styles, especially those that heavily rely on the forceful engagement of abdominal muscles during exhalation, may contribute to the development or exacerbation of elevated blood pressure. This could mean that individuals who habitually breathe in this manner, perhaps due to stress, certain physical activities, or even underlying respiratory conditions, might be at a higher risk of developing hypertension. Identifying such breathing patterns in patients diagnosed with hypertension could provide clinicians with valuable insights into the root cause of their condition, paving the way for more personalized and effective treatment strategies.
A Novel Therapeutic Target Emerges
The identification of the LPFR as a driver of hypertension immediately raised a critical question for the research team: could this specific brainstem region be a viable target for therapeutic intervention? The prospect of directly targeting brain regions with medication, however, presents significant challenges. "Targeting the brain with drugs is tricky because they act on the entire brain and not a selected region such as the parafacial nucleus," Professor Paton explained. The widespread effects of systemic brain medications can lead to a host of undesirable side effects, making them less than ideal for treating localized neurological dysfunctions.
A pivotal breakthrough in their research came with the discovery that the LPFR’s activity is not solely driven by internal brain signals but is also influenced by external sensory input. Specifically, the team found that the LPFR is activated by signals originating from the carotid bodies. These are small, specialized clusters of chemoreceptor cells located in the neck, near the bifurcation of the carotid artery. Their primary function is to monitor blood oxygen levels, but they also play a role in sensing carbon dioxide and pH. When the carotid bodies detect changes in blood gas levels, they send signals to the brain, including the brainstem, influencing vital functions like respiration and cardiovascular regulation.
This connection between the carotid bodies and the LPFR presented a potential workaround to the challenges of direct brain targeting. Because the carotid bodies are located outside the blood-brain barrier and are accessible to pharmaceutical agents, they offer a more feasible route for therapeutic intervention. "Our goal is to target the carotid bodies," Professor Paton stated, outlining their ambitious strategy. "We are importing a new drug that is being repurposed by us to quench carotid body activity and inactivate ‘remotely’ the lateral parafacial region safely, i.e., without needing to use a drug that penetrates the brain." This innovative approach, known as remote inactivation, holds the promise of modulating the LPFR’s activity without the systemic side effects associated with direct brain-acting drugs.
Broader Implications and Future Directions
The implications of this research extend beyond the general population with hypertension. It holds particular significance for individuals suffering from conditions like sleep apnea. Sleep apnea is characterized by repeated pauses in breathing during sleep, leading to intermittent drops in blood oxygen levels. These oxygen fluctuations are precisely the kind of stimuli that activate the carotid bodies. Consequently, individuals with sleep apnea often experience increased carotid body activity, which, in turn, could lead to sustained activation of the LPFR and contribute to the high prevalence of hypertension observed in this patient group. The WHO estimates that over 936 million people worldwide have moderate to severe obstructive sleep apnea.
The repurposing of existing drugs to target carotid body activity represents a cost-effective and potentially rapid pathway to developing new treatments. The researchers are actively exploring drugs that can selectively dampen the signaling from the carotid bodies, thereby indirectly inhibiting the hyperactive LPFR. This could involve drugs that modulate the chemosensory pathways within the carotid bodies or those that interfere with the neurotransmitters they release.
This discovery also opens new avenues for diagnostic approaches. If certain breathing patterns are confirmed to be strong indicators of LPFR overactivity, then non-invasive respiratory monitoring techniques could be employed to identify individuals at risk or those who might benefit from targeted interventions. Furthermore, understanding the precise neural circuitry involved could lead to the development of non-pharmacological therapies, such as specific breathing exercises or biofeedback techniques designed to retrain the respiratory control system and reduce reliance on forceful exhalations.
The research team is also keen to investigate the genetic and environmental factors that might predispose individuals to an overactive LPFR. Understanding these predispositions could lead to even earlier identification and prevention strategies. The long-term vision is to develop a comprehensive treatment paradigm for hypertension that incorporates this new understanding of brainstem control, potentially leading to a significant reduction in the global burden of cardiovascular disease. The journey from laboratory discovery to widespread clinical application is often lengthy, but this foundational research provides a compelling roadmap for future endeavors in the fight against hypertension.
